Our Programs
Our pipeline includes four clinical-stage drug candidates targeting different mechanisms critical to overcoming cancer progression and drug resistance:
- Zandelisib, an oral PI3K delta inhibitor;
- Voruciclib, an oral CDK inhibitor; and
- ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.
- Pracinostat, an oral HDAC inhibitor;
Our portfolio is built around drug candidates with validated targets and is designed to develop medicines that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other medicines.
Zandelisib Oral P13K Delta Inhibitor |
|||||
---|---|---|---|---|---|
INDICATION | COMBINATION | PHASE1/1B | PHASE2 | PHASE3 | COMMERCIAL RIGHTS |
Follicular Lymphoma Relapsed/refractory |
Monotherapy |
|
![]() ![]() U.S. co-promote; |
||
B-Cell Malignancies Relapsed/refractory |
Monotherapy Rituxan® (rituximab) Zanubrutinib2 |
![]() |
Voruciclib CDK Inhibitor |
|||||
---|---|---|---|---|---|
INDICATION | COMBINATION | PHASE1/1B | PHASE2 | PHASE3 | COMMERCIAL RIGHTS |
B-Cell Malignancies & AML Relapsed/refractory |
Monotherapy Venclexta® (venetoclax)3 |
|
![]() |
ME-344 Mitochondrial Inhibitor |
|||||
---|---|---|---|---|---|
INDICATION | COMBINATION | PHASE1/1B | PHASE2 | PHASE3 | COMMERCIAL RIGHTS |
HER2-Breast Cancer Treatment-naive, early stage |
Avastin® (bevacizumab)4 |
|
![]() |
Pracinostat HDAC Inhibitor |
|||||
---|---|---|---|---|---|
INDICATION | COMBINATION | PHASE1/1B | PHASE2 | PHASE3 | COMMERCIAL RIGHTS |
Myelodysplastic Syndrome Treatment-naive |
Vidaza® (azacitidine) |
|
![]() |
HDAC Inhibitor
Pracinostat HDAC Inhibitor
Myelodysplastic Syndrome
High & very high risk
Vidaza® (azacitidine)
PI3K Delta Inhibitor
Zandelisib (ME-401) PI3K Delta Inhibitor
Follicular Lymphoma
Relapsed/refractory
Single agent
B-Cell Malignancies
Relapsed/refractory
Single-agent
• Rituxan® (rituximab)
• Zanubrutinib‡
Selective CDK Inhibitor
Voruciclib CDK Inhibitor
B-Cell Malignancies
Relapsed/refractory
Single agent
Mitochondrial Inhibitor
ME-344 Mitochondrial Inhibitor
HER2-Breast Cancer§
Treatment-naïve, early stage
Avastin® (bevacizumab)
1 Phase 2 study to support an accelerated approval marketing application with FDA
2 Study arm initiated under clinical collaboration with BeiGene, Ltd.
3 Initiation of clinical studies is subject to opening of a new Investigational New Drug Application with FDA
4 Investigator-initiated trial